A Direct, Early Stage Guanidinylation Protocol for the Synthesis of Complex Aminoguanidine-containing Natural Products
September 9th, 2016
10.3K views
Here, we present a protocol for direct, early stage guanidinylation that enables rapid total synthesis of aminoguanidine-containing small organic molecules. An advanced synthetic intermediate used in the synthesis of a blood coagulation factor XIa inhibitor was prepared using this protocol.
Overview
This article presents a protocol for direct, early stage guanidinylation, facilitating the rapid total synthesis of aminoguanidine-containing small organic molecules. The method aims to streamline the preparation of linear aminoguanidine-containing compounds, which can enhance our understanding of their biological roles.
Key Study Components
Area of Science
- Synthetic Chemistry
- Natural Product Synthesis
- Medicinal Chemistry
Background
- Aminoguanidine-containing molecules are significant in medicinal chemistry.
- Reducing chemical transformations can improve synthesis efficiency.
- Guanidinylation can be strategically employed to maintain mass guanidine integrity.
- This approach can lead to better understanding of compounds for human health.
Purpose of Study
- To develop a streamlined synthetic method for aminoguanidine derivatives.
- To facilitate the preparation of natural and engineered compounds.
- To enhance the understanding of biological mechanisms related to these compounds.
Methods Used
- Direct synthetic approach for guanidinylation.
- Use of anhydrous dichloromethane as a solvent.
- Application of a protecting group strategy to avoid selectivity issues.
- Preparation of specific synthetic intermediates for further research.
Main Results
- Successful synthesis of aminoguanidine-containing small organic molecules.
- Demonstration of the efficiency of the early stage guanidinylation protocol.
- Preparation of a key synthetic intermediate for a blood coagulation factor XIa inhibitor.
- Potential implications for drug development and understanding biological processes.
Conclusions
- The protocol offers a rapid and efficient method for synthesizing important compounds.
- Early stage guanidinylation can significantly reduce the complexity of synthetic pathways.
- This approach may lead to advancements in medicinal chemistry and therapeutic development.
Frequently Asked Questions
What is guanidinylation?
Guanidinylation is a chemical modification process that introduces guanidine groups into molecules, enhancing their biological activity.
How does this method improve synthesis efficiency?
By reducing the number of chemical transformations required, this method streamlines the synthesis of complex molecules.
What are the potential applications of aminoguanidine-containing compounds?
These compounds can be used in drug development, particularly for conditions related to blood coagulation and other biological processes.
What role do protecting groups play in this protocol?
Protecting groups help maintain the integrity of the guanidine during subsequent reactions, preventing unwanted side reactions.
Can this method be applied to other types of molecules?
Yes, the principles of this method can be adapted for synthesizing various natural and engineered compounds.
Executive Industry Relevance
Direct early-stage guanidinylation streamlines the synthesis of aminoguanidine-containing natural products, reducing synthetic steps and improving route efficiency for target validation. This approach supports rapid generation of structurally complex scaffolds for preclinical evaluation of bioactive compounds. By preserving guanidine integrity through orthogonal protecting groups, the method enables reliable access to pharmacologically relevant motifs for mechanistic de-risking.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of guanidine-dependent biological activity in aminoguanidine-containing scaffolds.
- Operational Value: Reduces synthetic linear steps, accelerating access to target molecules for hypothesis testing.
- Predictive Value: Supports SAR exploration by providing consistent access to guanidine-modified analogs.
Screening & Assay Development
- Scientific Value: Produces pure, guanidine-intact compounds suitable for biochemical and cellular assays.
- Operational Value: Delivers reproducible material quality through standardized deprotection and purification.
- Assay Readiness: Avoids batch variability from incomplete protection or side reactions during synthesis.
Translational & Preclinical Research
- Translational Continuity: Facilitates synthesis of lead-like molecules for preclinical pharmacology and toxicity studies.
- Mechanistic De-risking: Confirms on-target effects by enabling structure-activity relationship studies.
- Risk-Adjusted Advancement: Supports go/no-go decisions based on reproducible synthetic access to active compounds.
Pipeline & Workflow Integration
The method fits within early discovery workflows, enabling rapid synthesis of aminoguanidine-containing hits for screening and lead optimization.
- Discovery Biology: Supports rapid SAR generation by providing reliable access to guanidine-modified compounds.
- Screening: Delivers assay-ready material with consistent purity and guanidine functionality.
- Analytics: Enables quantitative NMR and MS characterization of guanidine-containing intermediates and final products.
- Translational Research: Connects synthetic accessibility to preclinical evaluation of factor XIa inhibitor scaffolds.
- Enterprise Reuse: Platform adaptable to other diamine scaffolds for library generation of aminoguanidine analogs.
Operational & Enterprise Impact
- Scientific Value: Increases confidence in target engagement by enabling precise modification of guanidine-containing pharmacophores.
- Operational Value: Improves synthesis efficiency through step reduction and high-yield transformations.
- Strategic Value: Enhances capital efficiency by minimizing reagent use and purification burden.
- Portfolio Impact: Enables faster prioritization of aminoguanidine-containing candidates based on reliable synthesis.
Implementation Considerations
- Requires expertise in anhydrous and air-sensitive synthetic techniques.
- Needs Schlenk line, cannula transfer setup, and inert atmosphere capability.
- Demands careful selection of orthogonal protecting groups compatible with downstream reactions.
- Involves hazardous reagents (triphosgene, bromine) requiring fume hood and PPE use.
- Limited by solubility and stability of guanidine-protected intermediates during workup.
Biopharma FAQs
Why does direct guanidinylation improve target validation?
Direct guanidinylation reduces synthetic steps, enabling faster access to aminoguanidine-containing compounds for biological testing. By avoiding protecting group manipulations early in the sequence, it increases overall yield and purity. This supports more reliable target engagement assays and SAR interpretation.
How does isolating the isocyanate intermediate support discovery pipeline efficiency?
Isolating the isocyanate intermediate allows for controlled coupling with electrophiles like dibromophenol under mild conditions. This stepwise approach improves reaction control and minimizes side products. It enables parallel synthesis of analogs for rapid SAR exploration in early discovery.
What quantitative measurements confirm successful guanidine installation and deprotection?
Proton and carbon NMR spectroscopy in deuterated solvents confirm guanidine signal integrity after synthesis and deprotection. These analytical methods verify molecular structure and purity before biological evaluation. Consistent spectral data support reproducible compound generation for screening campaigns.
Why are replication requirements important for cross-functional collaboration in this workflow?
Reproducible synthesis ensures that medicinal chemistry, pharmacology, and DMPK teams receive identical material for testing. Consistent product quality reduces variability in assay results across sites. This alignment supports confident decision-making in lead optimization and preclinical development.
What statistical analysis is required before implementing this guanidinylation protocol in discovery projects?
Before implementation, teams should evaluate reaction yield consistency across multiple batches to assess robustness. Comparison of starting material conversion and product purity via HPLC or NMR provides quantitative benchmarks. These metrics help determine suitability for integration into parallel synthesis or automated workflows.
Chapters in this video
0:05
Title
0:41
Synthesis of Carbamate from Di-Boc Agmatine Isocyanate and 2,4-DibromoHGAL
3:12
Purification of Carbamate
5:53
Synthesis and Isolation of Clavatadine A
7:25
Results: Synthesis and Characterization of Clavatadine A and Its Precursors
8:19
Conclusion
